Furthermore, we blocked the TAK1-JNK/p38 signaling pathway with a TAK1 inhibitor (iTAK1), owing to which the effects of GCN5 overexpression were inhibited in both TAC- and PE-induced cardiac hypertrophy models. The gene discussed is KAT2A; the disease is cardiac hypertrophy.